Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked T-cell engager (TCE) that targets epidermal growth factor receptor ...
– Phase 1 trial supported by the Bill & Melinda Gates Foundation, the National Institute of Allergy and Infectious Diseases and conducted by the HIV Vaccine Trials Network – SAN FRANCISCO, Sept. 20, ...
– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine – – Phase 1 trial supported by the Bill & Melinda Gates Foundation, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results